Skip to content →

CEMET GmbH Posts

Low-fiber diet reduces gut microbiome diversity

Findings from microbiologists at Stanford University revealed that low-fiber diet considerably reduces the diversity of the gut microbiome.

The researchers fed human fecal samples to germ-free mice to colonize their gastrointestinal tract with a human gut microbiome. Over a period of seven weeks, some of the mice received low-fiber diet and others received a diet rich in fiber. For mice that received a low-fiber diet, the researchers observed a dramatic decline in bacterial diversity. The abundance of about 60% of the bacterial species were considerably decreased. The bacterial diversity of the gut microbiome of mice that received high-fiber, however, was largely unaffected.

These findings underpin the close relationship between diet and the bacterial composition of the gut microbiome.


Comments closed

Asklepios clinics founder Dr. Broermann invests in the start-up company CeMeT based in Tübingen

Gut bacteria and microbiome: important fields for precision medicine in the future

Tübingen, 2017/01/09 – The founder and sole shareholder of the private Asklepios clinics, Dr. Bernard große Broermann, has assumed a 40% shareholding of Center for Metagenomics, CeMeT GmbH. With the Tübiom project (, CeMeT is building one of the world’s largest microbiome reference database. The aim is to better understand the influence of the gut bacteria in diseases such as cancer, Alzheimer’s disease and diabetes, as well as vitamin deficiencies. Just a few weeks ago, during an event organized by the German Newspaper DIE ZEIT, Dr. Broermann officially announced that Asklepios will intensify its engagement in the field of precision medicine.

The causes of many diseases are unknown and medication is currently only prescribed on a statistical basis. With precision medicine on the rise, a different approach is developing including evaluating genetic variants, the environment and other factors such as the bacteria populating the gut.

As part of this new involvement, the capital of CeMeT has been increased by several million Euros. The founding shareholders of CeMeT, the professors Ingo Autenrieth, Daniel Huson and Detlef Weigel from Tübingen, and CeGaT GmbH, remain part of the company and together hold 55.6% of the shares.

In 2016, more than 600 million dollars were invested into microbiome research. This research field is rapidly increasing and more and more research groups and companies have the need for microbiome analysis and interpretation. The importance of microbiome research is demonstrated by the launch of the “National Microbiome Initiative” by the American government earlier this year. In addition to the Tübiom project, CeMeT has been a service partner of universities and clinics in the field of microbiome analysis since it was founded in 2014. Analysis is performed using state of the art techniques.

CeMeT and Asklepios clinics

In 2014, three well-known scientists and a renowned laboratory for human genetic diagnostics, founded a microbiome company called CeMeT. At the same time, professors Ingo Autenrieth, Daniel Huson and Detlef Weigel in cooperation with CeGaT GmbH started one of the world’s largest microbiome projects – the Tübiom. The aim of the project is to make microbiome analysis fit for diagnostic use by creating a reference database. With the founder of the Asklepios clinics as an additional shareholder of CeMeT, the company is supported by 45,000 employees and more than two million patients a year. CeMeT now combines the advantages of being fast and flexible typical for a small company with the possibilities of a large organization. In their everyday business, CeMeT offers microbiome analysis (16S and shotgun) to customers in research and industry. The company combines expertise in pre-analytics, sequencing, data analysis, microbiology and medicine.

Comments closed

Meet CeMeT

You can visit us at our booth at the following events:

Event Date City
ICMI 2015 14. – 18.07.2015 Berlin
DGKJ-Jahrestagung 02. – 05.09.2015 München
Viszeralmedizin 17. – 19.09.2015 Leipzig
67. Annual Meeting of the DGHM 27. – 30.09.2015 Münster
Joint Annual Meeting of the DGI & DZIF 19. – 21.11.2015 München
Leave a Comment

CeMeT – Center for Metagenomics: A milestone for the future of medicine in Tübingen

Three professors from Tübingen and CeGaT GmbH found CeMeT GmbH for determination, analysis and evaluation of the human metagenome for medical, dental and veterinary issues.

Microbiota summarizes the microorganisms of a particular habitat. It includes useful and harmful bacteria as well as viruses, fungi, and parasites that are found on skin, mucous membranes, or in the human intestine. An ecosystem is formed in which interactions between microorganisms may have both positive and negative effects on human health. The metagenome is the genetic information of the entire microbiota.

The importance of microbiota in the development of chronic diseases is increasingly becoming the focus of research and medicine. “We are convinced that metagenome information will be of high interest for patient care in the near future,” said Professor Ingo Autenrieth, Medical Director of the Institute for Medical Microbiology and Hygiene, University Hospital of Tübingen and one of the founding partners of CeMeT. For example, in recent years many causal correlations have been shown between the microbiota in the intestine and diseases such as inflammatory bowel disease, diabetes, cancer, multiple sclerosis, asthma, and obesity. “The determination and analysis of the metagenome will be increasingly important in medicine to identify risk factors and to plan individual therapies,” adds Isabell Flade, Managing Director of CeMeT. In order to make this a reality, CeGaT has founded the CeMeT GmbH, together with the university professors Ingo Autenrieth, Daniel Huson, and Detlef Weigel, Director at the Tübingen Max-Planck-Institute. Professor Huson, a renowned bioinformatician and Professor Weigel, a leading global evolution and genome researcher, are able to evaluate huge amounts of data obtained in metagenome analysis. CeMeT is the first company that is dedicated solely to the topic of “metagenomics” to solve human medical, dental and veterinary issues. “The expertise we have at CeMeT, including pre-analysis, sequencing, data analysis, microbiology, and medicine is unique in Germany” said Dr. Dirk Biskup, CEO of CeGaT. “This will be of benefit to researchers as well as short- to medium-term to the patient. “It is CeMeT’s mission to determine, analyze and evaluate metagenomes using the latest state of the art technologies. The goal is to clarify medical issues from Tübingen, to lead medical diagnostics of the future.

Comments closed